ADP induces desensitisation of equine platelet aggregation responses: studies using ADP beta S, a stable analogue of ADP.

The research investigates how the pre-incubation of horse platelets with adenosine 5′-diphosphate (ADP) reduces their response to further ADP exposure, a process called desensitisation. The study uses ADP beta S, a stable ADP analogue, and suggests that this desensitisation likely involves the ADP receptor or proximal intermediates in the signal transduction pathway for ADP.

Research Context and Methods

• The basis of this research was the exploration of the process by which pre-incubation of equine or horse platelets with adenosine 5′-diphosphate (ADP) led to a decrease in their aggregation or clumping responsiveness to subsequent interactions with ADP.
• Aggregation responsiveness essentially refers to the platelets’ ability to clump together, a critical aspect of blood clotting. The reduction in this responsiveness due to pre-incubation with ADP is known as desensitisation.
• The scientists used ADP beta S or adenosine 5′-(beta-thio)-diphosphate, a stable version of ADP that isn’t broken down, to examine this process as it’s capable of inducing aggregation by interacting with the ADP receptor.

Key Findings

• The initial finding was that the process of desensitisation was homologous, meaning it was specific only to ADP; the response to other aggregation inducers such as platelet-activating factor, thrombin, collagen, 5-hydroxytryptamine or ionomycin remained unaltered.
• How ADP beta S was used in the desensitisation studies is noteworthy – any residual ADP was removed by adding apyrase, an enzyme that breaks it down.
• The research found that the platelet desensitisation to ADP beta S recovered fully within an hour after pre-treatment with ADP. Moreover, this was not brought on by an extracellular mediator, suggesting the phenomenon is likely an intracellular process.

Conclusions and Implications

• The researchers concluded that the mechanism of platelet desensitisation is likely linked to the ADP receptor or proximal intermediates in the ADP signaling pathway.
• Understanding these mechanisms could potentially have critical implications in fields such as hematology and cardiovascular therapy, where managing platelet responsiveness is often key to treatment.